On August 18, 2022, Think Bioscience, a synthetic biology company focused on developing small-molecule therapeutics that target difficult-to-drug proteins, announced it has raised $17 million in an oversubscribed seed round led by Innovation Endeavors and Xora Innovation, with participation from AV8 Ventures, Buff Gold Ventures, and LiquidMetal Ventures. Returning pre-seed investors include Xora, Wireframe Ventures, and Axial VC. Think is a spin-out from CU Boulder and is a client company of Innosphere Ventures' incubation program. Wilson Sonsini Goodrich & Rosati advised Think Bioscience on the transaction.

Think Bioscience is reimagining synthetic biology by using living systems to guide the design and assembly of better medicines. The unique approach to drug discovery combines applied microbiology, enzymology, and computational science to develop small-molecule therapeutics against elusive targets. The company is focused on several therapeutic areas including oncology, autoimmune, and metabolic disease.  

The Wilson Sonsini team that advised Think Biosciences on the transaction includes Mark Solakian, Priyanka Nawathe, and Drew Kohlmeier.

For more information, please see Think Biosciences’ press release.